Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1563384 | 0.84 | ALDH1A1 (0.48) | ALDH1A1CYP1A2CYP2C9GAAMEN1 | |
| SCHEMBL20456902 | 0.82 | ALDH1A1 (0.46) | ALDH1A1CYP1A2CYP2C9GAAMEN1 | |
| SCHEMBL30375313 | 0.81 | GAA (0.53) | ALDH1A1CYP1A2CYP2C9GAAMEN1 | |
| SCHEMBL2570420 | 0.81 | GAA (0.53) | ALDH1A1CYP1A2CYP2C9GAAMEN1 | |
| SCHEMBL18026637 | 0.81 | GAA (0.56) | ALDH1A1CYP1A2CYP2C9GAAMEN1 | |
| SCHEMBL28678791 | 0.79 | ALDH1A1 (0.49) | ALDH1A1CYP1A2CYP2C9GAAMEN1 | |
| SCHEMBL22833063 | 0.77 | GAA (0.51) | ALDH1A1CYP1A2CYP2C9GAAMEN1 | |
| SCHEMBL18652223 | 0.77 | GAA (0.51) | ALDH1A1CYP1A2CYP2C9GAAMEN1 | |
| Methyl Alcohol SCHEMBL28761646 | 0.77 | GAA (0.51) | ALDH1A1CYP1A2CYP2C9GAAMEN1 | |
| SCHEMBL30200909 | 0.76 | GAA (0.47) | ALDH1A1CYP1A2CYP2C9GAAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11628221-B2 | Peptide linker and combination for prodrugs activated by prostate-specific antigen | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2023-04-18 | — | — | US | disclosed |
| US-20220088209-A1 | PEPTIDE LINKER AND COMBINATION FOR PRODRUGS ACTIVATED BY PROSTATE-SPECIFIC ANTIGEN | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2022-03-24 | — | — | US | disclosed |
| US-11129901-B2 | Peptide-linked ester prodrugs activated by prostate-specific antigen | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2021-09-28 | — | — | US | disclosed |
| WO-2018144880-A1 | NEW PEPTIDE-LINKED ESTER PRODRUGS ACTIVATED BY PROSTATE-SPECIFIC ANTIGEN | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2018-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11628221-B2 | Peptide linker and combination for prodrugs activated by prostate-specific antigen | KLK3, DNPEP, FOLH1 | ALDH1A1 2579/4885CYP1A2 4748/4885CYP2C9 4588/4885 |
| US-20220088209-A1 | PEPTIDE LINKER AND COMBINATION FOR PRODRUGS ACTIVATED BY PROSTATE-SPECIFIC ANTIGEN | KLK3, DNPEP, FOLH1 | ALDH1A1 2579/4885CYP1A2 4748/4885CYP2C9 4588/4885 |
| US-11129901-B2 | Peptide-linked ester prodrugs activated by prostate-specific antigen | ACP3, KLK3, DNPEP | ALDH1A1 2127/4885CYP1A2 4533/4885CYP2C9 4368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.